Analysts have been eager to weigh in on the Healthcare sector with new ratings on Chemed (CHE) and Regeneron (REGN).
Chemed (CHE)
RBC Capital analyst Frank Morgan maintained a Buy rating on Chemed today and set a price target of $535.00. The company’s shares closed last Monday at $448.26.
According to TipRanks.com, Morgan is a 5-star analyst with an average return of 9.9% and a 61.7% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care, Genesis Healthcare, and Acadia Healthcare.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chemed with a $535.00 average price target.
See today’s analyst top recommended stocks >>
Regeneron (REGN)
RBC Capital analyst Kennen MacKay maintained a Hold rating on Regeneron today and set a price target of $533.00. The company’s shares closed last Monday at $564.11, close to its 52-week high of $572.50.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 9.1% and a 53.5% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, BioMarin Pharmaceutical, and Five Prime Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $486.90 average price target, which is a -14.4% downside from current levels. In a report issued on April 8, Benchmark Co. also initiated coverage with a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
